|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.40 EUR | -0.68% |
|
+9.55% | +72.91% |
| 12-04 | Evotec's Partner Bayer Starts Mid-stage Study of Genetic Kidney Disease Drug | MT |
| 12-04 | Bayer Starts Phase IIa Study for Treatment of Patients with Alport Syndrome | CI |
d820a0b0333f9b2894.sahBBLIXmHSzco9SeJegHn82aO67llBAXtzw4dwcSg0.09wCXud5zhX5R8BnG-flTUliMZjswRtzMrOYj6xbEFiFxBgw4mW1O4Mt3g~3cd15e285a6bc98d61a0bc609bcb8507
- Stock Market
- Equities
- BAYN Stock
- Charts Bayer AG
- News Chart
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















